NY-IFF
IFF (NYSE:IFF) today released its 2022 Do More Good Report, which highlights performance and progress against goals set forth in the Do More Good Plan, the Company’s environmental, social, governance, plus sustainable solutions (or ESG+) strategy and roadmap that activates its purpose of applying science and creativity for a better world.
The Do More Good Report: IFF’s 2022 ESG+ Progress, describes the first full year of performance and progress as One IFF following the 2021 merger with DuPont’s Nutrition & Biosciences division. IFF will hold a live webcast to discuss the Company’s Do More Good Plan and goals, 2022 ESG+ results, and 2023 sustainability outlook on May 23, 2023, at 9:00 a.m. ET.
“When we launched our Do What Matters Most strategy in 2022, we committed to embedding ESG+ in all we do,” said Frank Clyburn, IFF CEO. “Our 2022 Do More Good Report illustrates the steps we’re taking to deliver on our commitments to address sustainable development imperatives. Our world-class R&D program and commitment to innovation fuels a pipeline of exciting sustainable solutions that are helping our customers reach their ESG goals and, in turn, responding to heightened consumer expectations on sustainability.”
The 2022 Do More Good Report is organized according to the four pillars of the Do More Good Plan, which reflect the areas where the Company can have the greatest positive impact in addressing the world’s most pressing sustainable development challenges: Sustainable Solutions; Climate & Planetary Health; Equity & Wellbeing; and Transparency & Accountability.
2022 performance highlights and achievements by IFF include:
- Recognized externally for ESG leadership, including being named to the Dow Jones Sustainability Indices for the third consecutive time, and maintaining the 2022 EcoVadis platinum sustainability rating, placing IFF among the top 1% of companies assessed;
- Enabled customers and consumers to save more CO2e than generated at IFF’s own manufacturing sites by accelerating the wider adoption of sustainable solutions in the marketplace, as documented by life cycle assessments;
- Named to the CDP Climate A list for the eighth consecutive year and completed its first virtual power purchase agreement, expected to cover approximately 30% of the total electricity needs of its European sites when it becomes operational at full capacity in 2024;
- Recertified as EDGE Move level globally for its commitment to gender parity, and included in the Bloomberg Gender-Equality Index for the second time;
- Introduced a Global Parental Leave Policy that grants a minimum of 16 weeks of 100% paid leave for a new IFF parent, regardless of gender identity or expression;
- Linked ESG performance metrics for reduction of greenhouse emissions and increases in company-wide gender representation to the Annual Incentive Plan Award for executive leaders, impacting 2022 variable compensation by 5%;
- Completed updates to its Code of Conduct training and certification campaign, achieving a 99.8% acknowledgment rate among employees.
To learn more, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.
Webcast
IFF will hold a live webcast to discuss the Company’s Do More Good Plan, 2022 key performance metrics, progress against 2030 goals and 2023 outlook on May 23, 2023 at 9:00 a.m. ET., where Mr. Clyburn will be joined by Michael DeVeau, Senior Vice President, Corporate Finance and Investor Relations; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Ralf Finzel, Chief Operations Officer; Deborah Borg, Chief Human Resources, Diversity, Equity & Inclusion and Communications Officer; and Jennifer Johnson, General Counsel and Corporate Secretary. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.
IFF invites investors, analysts and all IFF stakeholders to participate by phone by calling 1-404-975-4839 from the United States and toll-free from other locations by calling +1-833-470-1428. The access code for the conference call is 758853, and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, IFF will post a recorded version on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
